In prostate cancer cell line PC-3, gene silencing of Toll-like receptor-9 (TLR9), reversed migration and invasiveness and resulted in downregulation of a number of genes including LURAP1L [50]. This evidence concerns the gene LURAP1L and prostate carcinoma.